The following email speaks for itself.....
----- Forwarded Message -----
From: CARL TUTTLE <runagain@comcast.net>
To: thart15@jh.edu <thart15@jh.edu>
Cc: kremington@ktvn.com <kremington@ktvn.com>; producers@ktvn.com <producers@ktvn.com>
Sent: Sunday, May 17, 2026 at 09:16:59 AM EDT
Subject: Health Watch: Lyme disease vaccine
KTVN 2 News Nevada
Kristen Remington Anchor/Reporter
Health Watch: Lyme disease vaccine
https://www.youtube.com/watch?v=CeQqN7Lvr3E
Quote:
“There used to be a Lyme disease vaccine called LYMErix in the late 90’s and early 2000’s. This was eventually pulled off the market due to low sales.” -Thomas M. Hart, PhD
Thomas M. Hart, PhD
Johns Hopkins Bloomberg School of Public Health
615 N. Wolfe Street, E5638
Baltimore Maryland 21205
Dr. Hart,
“Low sales” of the LYMErix vaccine is not the entire truth and has been regurgitated across mainstream media.
The vaccine known as LYMErix was supposed to expose the immune system to the outer surface protein A (OspA) of the spirochete responsible for causing Lyme disease but for some patients, it caused the same crippling effects of the disease itself as reported in the class action lawsuit:
https://www.dropbox.com/s/sodqs3pdeeesktf/Sheller%20Lymerix.pdf?dl=0
Excerpt from the lawsuit:
“The people who have contacted us were, prior to vaccination with LYMErix, healthy, active and energetic. Indeed, the very reason they sought the LYMErix vaccine was their desire to preserve their healthy, active lifestyle. However, what they experienced was a dramatic degradation of their health and quality of life. As will be described below, these previously healthy individuals are now afflicted with painful, at times debilitating arthritic symptoms, including joint pain and swelling, as well as extremely severe Lyme-disease-like symptoms which have persisted to this day.”
Below is the link to the Final Judgement and Approval of the class action against SmithKline Beecham as a settlement was awarded to these individuals.
JUDGEMENT, FINAL ORDER AND DECREE GRANTING FINAL APPROVAL OF THE CLASS ACTION SETTLEMENT:
A chronic relapsing seronegative disease does not fit the vaccine model so chronic Lyme which is completely devastating to the patient is not recognized and there is no treatment. The disabled Lyme patient is left to fend for himself because treating this class of patient became too expensive as outlined in the racketeering lawsuit. There is a growing community of horribly disabled patients whose disability has gone unrecognized for three decades.
Here’s yet another victim:
Nicole Malachowski: Unfit for Duty from Debilitating Tick-Borne Disease
http://cdmrp.army.mil/cwg/stories/2018/nicole_malachowski_profile
“Her medical retirement, however, was premature. At only 43 years old, she was deemed unfit for duty due to neurological damage from tick-borne illness.”
The latest vaccine from French drug manufacturer Valneva is another OspA vaccine similar to LYMErix so the possibility exists that the class of patient who experienced the debilitating effects of LYMErix could end up with the same results. There was no attempt to uncover why LYMErix disabled the patient as described in the class action. Until we fully understand how Lyme disease disables its victim aren’t we playing Russian roulette with people’s health?
Respectfully Submitted,
Carl Tuttle
Independent Researcher
Hudson, NH
Suppressing evidence of persistent infection after antibiotic treatment for Lyme disease is not collaboration, it is collusion:
Peer Reviewed Evidence of Persistence of Lyme Disease Spirochete Borrelia burgdorferi and Tick-Borne Diseases (700 references)
https://www.dropbox.com/s/n09sk90eo6xz7ua/700%20articles%20LYME%20EvidenceofPersistence-V2.pdf?dl=0